CureVac N.V. (5CV.DE) XETRA
Currency In EUR
- General
- Statistics
- Historical Data
- Profile
- Financials
CureVac N.V.
Address
Friedrich-Miescher-Strasse 15
Tübingen, 72076
Germany
Phone
49 7071 9883 0
Website
Sector
Healthcare
Industry
Biotechnology
Employees
825
First IPO Date
August 25, 2020
Key Executives
| Name | Title | Pay | Year Born |
| Alexander Zehnder | Chief Executive Officer, MD & Member of Management Board | 929,699 | 1970 |
| Ulrike Gnad-Vogt | Senior Vice President & Area Head of Oncology | 284,145 | 1973 |
| Axel-Sven Malkomes | Chief Financial Officer & Member of Executive Board | 486,661 | 1967 |
| Malte Greune | Chief Operating Officer, Member of Management Board & MD | 540,751 | 1965 |
| Thaminda Ramanayake | Chief Business Officer & Member of Executive Board | 586,630 | 1977 |
| Myriam Mendila | Chief Scientific Officer, Head of R&D, MD & Member of the Management Board | 605,480 | 1966 |
| Patrick Baumhof | Senior Vice President of Technology | 0 | N/A |
| Sarah Fakih | Vice President of Corporate Communications & Investor Relations | 0 | N/A |
| Slavica Stevanovic-Heck | Head of Human Resources | 0 | N/A |
| Marco Rau | General Counsel | 0 | N/A |
Description
CureVac N.V. is a biopharmaceutical entity operating in the clinical development phase, focused on pioneering revolutionary medicines utilizing messenger ribonucleic acid (mRNA) technology. Its portfolio includes prophylactic vaccines such as the mRNA-based candidate CV2CoV, currently in Phase 1 clinical trials for SARS-CoV-2. Another mRNA vaccine, CV7202, has successfully concluded Phase 1 trials for rabies, while CVSQIV is in Phase 1 development against influenza. The company is also advancing therapies for lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and universal influenza. Furthermore, CureVac is actively developing RNA-based immunotherapies for cancer, exemplified by CV8102, which is presently in Phase 1 clinical evaluation for cutaneous melanoma, adenoidcystic carcinoma, and squamous cell cancers affecting the skin, head, and neck. The company was established in 2000 and maintains its main office in Tübingen, Germany.
